F Abb Vie Inc. Transaction History

F

$2.83 Billion
Q3 2024

A detailed history of F transactions in Abb Vie Inc. stock. As of the latest transaction made, F holds 52,145 shares of ABBV stock, worth $8.75 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

52,145

Previous 55,856 6.64%

Holding current value

$8.75 Million

Previous $9.58 Million 7.48%

% of portfolio

0.36%

Previous 0.35%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$163.84 - $199.33 $608,010 - $739,713	-3,711 Reduced 6.64%	52,145 $10.3 Million
Q2 2024 Jul 29, 2024	BUY	$154.79 - $180.76 $8.41 Million - $9.82 Million	54,351 Added 3611.36%	55,856 $9.58 Million
Q1 2024 Apr 23, 2024	BUY	$159.82 - $182.1 $23,173 - $26,404	145 Added 10.66%	1,505 $274,000
Q4 2023 Feb 01, 2024	SELL	$137.6 - $154.97 $9,769 - $11,002	-71 Reduced 4.96%	1,360 $210,000
Q3 2023 Nov 06, 2023	BUY	$133.59 - $154.65 $191,167 - $221,304	1,431 New	1,431 $213,000
Q4 2022 Jan 31, 2023	BUY	$138.31 - $165.87 $176,345 - $211,484	1,275 New	1,275 $206,000
Q2 2022 Jul 20, 2022	SELL	$137.62 - $174.96 $1,513 - $1,924	-11 Reduced 0.56%	1,962 $221,000
Q1 2022 Apr 22, 2022	BUY	$131.98 - $163.75 $1,187 - $1,473	9 Added 0.46%	1,973 $319,000
Q3 2021 Nov 01, 2021	BUY	$106.4 - $120.78 $212 - $241	2 Added 0.1%	1,964 $212,000
Q2 2021 Aug 10, 2021	SELL	$105.21 - $117.21 $177,278 - $197,498	-1,685 Reduced 46.2%	1,962 $220,000
Q1 2021 Jun 01, 2021	BUY	$102.3 - $112.62 $166,237 - $183,007	1,625 Added 80.37%	3,647 $395,000
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $162,750 - $219,730	2,022 New	2,022 $217,000

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $297B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F, based on Form 13F filings with the SEC.

News

Stay updated on F with notifications on news.

Account